Trial Profile
Pre-surgical Evaluation of MK-2206 in Patients With Operable Invasive Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs MK 2206 (Primary)
- Indications Adenocarcinoma; Breast cancer
- Focus Therapeutic Use
- 01 Aug 2021 Results (n=7) of a proof of principle study assessing whether Diffuse optical tomography breast imaging system-derived measurements are modifiable with targeted therapies ; patients were enrolled from three clinical studies: NCT02598557, NCT01319539 and NCT02712723 published in the Breast Cancer Research and Treatment
- 05 Jun 2018 Results assessing the impact of Akt inhibition on the tumor microenvironment, presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 09 Dec 2017 Results assessing tumor immune environment in Breast cancer patients presented at the 40th Annual San Antonio Breast Cancer Symposium.